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Abstract
Although cancer survival in general has improved in Australia over the past 30 years, Indigenous Australians,
socioeconomically disadvantaged persons, and people living in remote areas still experience poorer health
outcomes. This paper aims to describe the development of CancerCostMod, and to present the healthcare
expenditure and patient co-payments for the first 12-months post-diagnosis. The base population is a census
of all cancer diagnoses (excluding non-melanoma skin cancer) in Queensland, Australia between 1 July 2011
and 30 June 2012 (N = 25,553). Each individual record was linked to their Queensland Health Admitted Patient
Data Collection, Emergency Department Information System, Medicare Benefits Schedule, and Pharmaceutical
Benefits Scheme records from 1 July 2011 to 30 June 2015. Indigenous status was recorded for 87% of
participants in our base population. Multiple imputation was used to assign Indigenous status to records
where Indigenous status was missing. This base population was then weighted, using a programmed SAS
macro (GREGWT) to be representative of the Australian population. We adopted a national healthcare
perspective to estimate the cost of cancer for hospital episodes, ED presentations, primary healthcare, and
prescription pharmaceuticals. We also adopted an individual perspective, to estimate the primary healthcare
and prescription pharmaceutical patient co-payments. Once weighted, our sample represents approximately
123,900 Australians (1.7% Indigenous Australians). The total healthcare system cost of all cancers during the
first 12-months post diagnosis was $4.3 billion, and patient co-payments costs were $127 million. After
adjusting for sex, age at diagnosis, Indigenous status, rurality, socioeconomic status, and broad cancer type,
significant differences in costs were observed for population groups of interest within the first year post-
diagnosis. This paper provides a more recent national estimate of the cost of cancer, and addresses current
research gaps by highlighting the distribution of healthcare and individual costs by Indigenous status, rurality,
and socioeconomic status.
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Introduction
In Australia, the overall cancer mortality rate decreased by
23% between 1982 and 2017 [1]. However, three popula-
tion groups experience poorer cancer outcomes compared
to the general Australian population: Australian Aborigi-
nal and/or Torres Strait Islander people (hereafter respect-
fully referred to as Indigenous people), socioeconomically
disadvantaged persons, and people living in remote areas
[1]. To add to the complexity of this issue, these popula-
tion groups often overlap. Indigenous people more often
live in remote and very remote areas [2], and a greater
proportion of people living in rural and remote areas ex-
perience socioeconomic disadvantage [3]. A recent study
found that the socioeconomic disparities in cancer sur-
vival appear to have worsened over the past 30 years. The
gap remained after accounting for diagnosis stage, and
cancer site [4].
A number of factors have been identified in contributing
to these survival inequalities, including but not limited to
differences in risk factors [1, 5], being diagnosed at a later
stage [5, 6], differences in access to oncology services [7,
8], a greater number of comorbidities [6], and differences
in treatment [6, 9–11]. High patient out-of-pocket ex-
penditure (OOPE) may also impact a person’s decision to
access care, with one study finding 21% of people with
cancer skipping healthcare due to the cost [12], and an-
other study found that 11% of patients found that pre-
scriptions relating to their oncology treatment caused
financial burden [13]. A recent study reported that the
median total cost to the patient for provider fees during
the first 2 years was over $20,000 for people diagnosed
with lung or breast cancer [14]. Studies using self-reported
costs, have found that OOPE is higher for those who have
to travel to receive treatment, due to travel and accommo-
dation costs [15, 16].
The healthcare system expenditure for cancer is also
high [17–19]. A commissioned report estimated that
the lifetime costs of cancer for a patient diagnosed in
New South Wales (NSW), Australia, in 2005 was $3.9
billion [17]. These costs are expected to rise with new
technologies, new pharmacotherapies, and population
changes [20]. This predicted increase in costs has
already been seen with the annual Pharmaceutical Ben-
efits Scheme (PBS) expenditure on anticancer drugs in-
creasing by approximately $400 million between 1999
and 2000 and 2010–11. This was an average increase of
19% compared to 9% for all other drugs combined [21].
The Australian Institute of Health and Welfare (AIHW)
reported that cancer cost approximately $4.5 billion in
2008–09 (excluding screening). The majority of these
costs were due to hospital admitted patient services
(79%), followed by prescription pharmaceuticals (12%),
and out-of-hospital costs, such as general practitioner,
specialists, pathology, and imaging (9%) [18]. However,
these reports are now a decade old, and do not look at
the distribution of costs by population group. To the
author’s best knowledge, only one report has compared
the cost of hospital expenditure by Indigenous status.
The AIHW and Cancer Australia reported that in
2010–11, the per person hospital expenditure for all
cancers combined for Indigenous Australians was half
of that for non-Indigenous Australians [19].
CancerCostMod is Australia’s first model of health ser-
vice use, healthcare expenditure, and patient co-payments
for people diagnosed with cancer in Australia. This model
has several objectives:
1. To quantify the current health system use, and
healthcare expenditure for people with cancer, and
to determine any inequalities by Indigenous status,
socioeconomic status, and remoteness;
2. To quantify the patient co-payment for people
with cancer, and to determine any inequalities by
Indigenous status, socioeconomic status, and
remoteness;
3. To estimate the costs to government and
individuals of “optimal service use” - if all patients
received the maximum access of care.
This paper aims to 1) describe the development of our
model, CancerCostMod; 2) to describe the total costs of
cancer in Australia during the first 12-months post-diag-
nosis; and 3) to describe the distribution of the cost of
cancer in Australia during the first 12-months post-diag-
nosis by population group.
Methods
Base population – Linked administrative data
The protocol describing the data linkages that were under-
taken to create this dataset has been described previously
[22]. Briefly, the base population for this model was a cen-
sus of all patients diagnosed with cancer in Queensland
between 1 July 2011 and 30 June 2012, as recorded by the
Queensland Cancer Registry (QCR) (N = 25,553 patients).
Each individual’s QCR record was linked to their Queens-
land Health Admitted Patient Data Collection (QHAPDC)
records (243,034 separations for 21,944 patients), and
Queensland Health Emergency Department Information
Systems (EDIS) (46,455 presentations from 12,825 pa-
tients) from 1 July 2011 to 30 June 2015. This linkage was
conducted by the Queensland Health Statistical Services
Branch using deterministic and probabilistic methods.
Each participant’s record was then linked to their individ-
ual Medicare Benefits Schedule (MBS) (6,058,380 services)
and Pharmaceutical Benefits Scheme (PBS) (2,619,712
prescriptions) records from 1 July 2011 to 30 June 2015
by the Data Linkage Unit at the AIHW using probabilistic
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linkage. Overall, 99.4% of cohort members were matched
to the Medicare enrolments register.
The QCR dataset contained date of diagnosis, Inter-
national Classification of Diseases for Oncology (ICD-O)
morphological code, ICD-O topographical code, differen-
tiation code, behaviour status, as well as date and cause of
death if applicable. The stage at diagnosis is not routinely
collected by the QCR. Other variables included sociode-
mographic information, such as date of birth, sex, Indi-
genous status, and postcode at diagnosis.
The QHAPDC records contained information on all
separations from a private or public hospital in Queens-
land. Facility number, patient residential postcode, admis-
sion and separation date, length of stay, hospital insurance
status, and the Australian Refined Diagnostic-Related
Group (AR-DRG) was recorded for each separation. The
AR-DRG is a classification system, where episodes of care
are coded using the ICD-10-Australian Modification
(ICD-10-AM) and Australian Classification of Health In-
terventions, which is used to code procedures and inter-
ventions [23]. The EDIS dataset contained all emergency
department (ED) presentations, including information
such as date of presentation, facility number, patient post-
code at time of presentation, triage category (Australasian
Triage Scale for treatment prioritisation), discharge des-
tination, and ICD-10-AM code.
MBS data include individual patient identifier, patient
postcode, date of service, provider postcode, MBS item
code, fee charged, benefit paid (by MBS), patient
co-payment costs, and hospital flag. MBS claims data
exclude Department of Veteran’s Affairs beneficiaries.
PBS data includes individual patient identifier, patient
postcode, date of supply, PBS item, patient category
(concession or general), patient co-payment costs,
benefit amount, pharmacy postcode. PBS data excludes
private prescriptions, over-the-counter medications,
under co-payment prescriptions, Repatriation Pharma-
ceutical Benefits Scheme prescriptions, and any medi-
cations dispensed under special arrangements.
Development of CancerCostMod
Cancer classification
Using the ICD-O 3rd Edition [24] and the Cancer
Council Queensland methods website [25], the type of
cancer was grouped into 18 broad cancer categories:
head and neck; digestive organs; colorectal cancer; fe-
male genital organs; breast cancer; prostate cancer;
male genital organs excluding prostate; urinary tract;
eye, brain and other parts of the central nervous sys-
tem (CNS); mesothelioma, Kaposi sarcoma and soft
tissue; thyroid and other endocrine organs; other thor-
acic and respiratory organs; bone; tracheal, bronchus
and lung cancer; other skin; melanoma; blood and
lymphatic system; other or ill-defined cancers.
Socioeconomic status and rurality
The patient’s postcode at diagnosis was mapped to the
Australian Bureau of Statistics (ABS) Index of Relative
Socio-Economic Disadvantage (IRSD), and Australian
Statistical Geography Standard (ASGS) [26]. IRSD is a
summary of the economic and social conditions of an
area, and is a measure of relative disadvantage only,
where decile 1 was the most disadvantaged, and decile
10 was the least disadvantaged. ASGS has five categor-
ies ‘metropolitan’, ‘inner regional’ ‘outer regional’, and
‘remote’ and ‘very remote’. There were 151 records with
‘unknown or not stated’ postcodes at diagnosis, which
could not be mapped to IRSD or rurality. We have
categorised these records as ‘unknown or not recorded’
for IRSD and rurality. For our analyses, we collapsed
rurality into three categories (‘metropolitan’, ‘regional’,
and ‘remote’) and IRSD into quintiles (Q1: most disad-
vantaged and Q5: least disadvantaged).
Indigenous status
A common data limitation in Australia is that Indigenous
status may be incompletely recorded in health and vital
registration data collections [27]. The Australian Cancer
Database considers five (of eight) jurisdictions to have
sufficient completeness for reporting purposes, NSW,
Victoria, Queensland, Western Australia and the North-
ern Territory [1]. A 2011–12 audit found that Indigenous
status in Queensland Health hospital admission records
had 87% weighted completeness (CI 84–91%) [27].
Indigenous status was recorded for 87% of partici-
pants in our original cohort from the QCR dataset.
We used a number of methods to assign Indigenous
identification to the 13% of records for which there
was missing data or ‘unknown’ Indigenous status re-
corded (n = 3316). Initially, records with missing or
unknown Indigenous identification on the QCR data-
set were assigned to be ‘Indigenous’ if they resided in
a local government area (LGA) that had greater than
or equal to 75% of the population identified as Indi-
genous, as reported by the ABS’ estimated resident In-
digenous Australian and non-Indigenous Australian
populations in each Queensland LGA for 2011 [28].
Seventy-five percent was chosen as a conservative
cut-off, reflecting the definition by the ABS of a
‘Discrete Indigenous Community’ as one that has
greater than half of the population identifying as Abo-
riginal and/or Torres Strait Islander [29].
We then used multiple imputation (MI) to impute the
remaining missing values for Indigenous status (n = 3297).
We used the MI procedure in SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA), which has three distinct phases [30]. We
used logistic regression to develop the imputation model
for multiple imputation, as the variable of interest was di-
chotomous (Indigenous or not-Indigenous). Covariates
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used were similar to those used by Morell et al. [31],
and included sex, 5-year age group, 12-month survival,
country of birth (Australia, not Australia, or not stated/
unknown), broad cancer group (18 categories), rurality
(5 categories), and IRSD deciles. We used PROC MI
with a monotone logistic statement, with 20 imputa-
tions, followed by PROC LOGISTIC, and finally PROC
MIANALYZE to produce inferential results.
Weighting to the Australian population
In order to provide results that are representative to the
Australian population, we used the programmed SAS macro
GREGWT to weight our dataset to the Australian popula-
tion. GREGWT is a generalised regression reweighting algo-
rithm which was developed by the ABS and is commonly
used to weight their household surveys against known
benchmarks [32]. The mathematical techniques underlying
GREGWT have been described elsewhere [33, 34]. In the
current study, data were benchmarked against the 2012
Australian Cancer Database [35]. This database provides
Australia-wide cancer incidence rates stratified by cancer
type, age group and gender. Cancer incidence rates for 2012
were extracted from this database and used as the bench-
mark for the calculation of weights in the current study.
Defining costs
We developed CancerCostMod to allow analyses of costs
from different perspectives. We adopted a national health-
care perspective, to estimate the direct cost of cancer to
the healthcare system for hospital, primary healthcare and
prescription pharmaceuticals. We also adopted an individ-
ual perspective, to estimate the patient co-payments for
primary healthcare and prescription pharmaceuticals.
All costs were calculated monthly for each individual from
the date of diagnosis (t = 0) for 36 months. If an individual
had no health services for the month, the cost was recorded
as $0. All costs are reported in Australian dollars (AUD),
and were adjusted to the 2016–17 financial year using the
Reserve Bank of Australia inflation calculator [36].
Hospital costs
Within Australia, public hospitals are run by the State and
Territory governments, and are jointly funded by the state
and national governments through either activity-based
funding (ABF) or block funding [37]. The ABF model pays
hospitals for the number and mix of services provided, and
accounts for patients that may be more complicated. The
Independent Hospital Pricing Authority (IHPA) was estab-
lished as part of the National Reform Act 2011, and is re-
sponsible for the implementation of the ABF for public
hospitals. The IHPA produces an annual National Hospital
Cost Data Collection (NHCDC), which includes the volun-
tary submission of cost data for each AR-DRG from public
and private hospitals. This information is then used to
develop the National Efficient Price, which determines the
federal contribution to the ABF system, and the National
Efficient Cost, which determines the federal contribution
to block funding. Each State and Territory is then respon-
sible for distributing the federal and state funding to their
public hospitals. The annual NHCDC reports are available
online [38–41]. Private hospitals are owned and operated
by private institutions but must still comply with national
standards. Private hospitals receive funding from patient
charges, private insurance, and Medicare rebates [42].
The cost attributed to each AR-DRG for public hospital
separations was assigned using the actual cost as reported
by the NHCDC Report (available online) [38–41] for the
relevant year. To reflect possible variations in the costs of
delivering healthcare to some individuals, we included the
adjustment for certain patient demographics produced by
the IHPA (pediatric, patient remoteness and/or Indigen-
ous person, and private patient service and accommoda-
tion) [43–45]. As there were no adjustments published for
the 2011–12 financial year, we used the adjustment for the
2012–13 period. The cost attributed to each AR-DRG for
private hospital separations was assigned for the relevant
year using the average charge per separation reported by
the Private Hospital Data Bureau Annual Reports (avail-
able online) [46].
In Australia, some patients may receive treatment as a
non-admitted (out-) patient at a hospital location, but are
not formally ‘admitted’, and are therefore not captured in
the QHAPDC dataset. In order to capture these non-ad-
mitted hospital services, we included MBS items which re-
lated to services or procedures performed in a hospital
setting. This method has been used in previous Australian
studies [47, 48]. We identified these MBS items by con-
ducting a keyword search of the MBS item descriptions to
identify hospital items: ‘hospital’ (excluding codes which
specified it was in a place ‘other than a hospital’), ‘theatre’,
‘emergency department’, and ‘prior to discharge’. Item
codes relating to chemotherapy and radiotherapy were
also identified through consultation with staff from the
Townsville Hospital and Health Service, Townsville Can-
cer Centre. The rebate paid by Medicare for MBS codes
for these ‘hospital’ items were included in the hospital
costs. Hereafter, admitted and non-admitted hospital epi-
sodes will be referred to as ‘hospital episodes’.
The ED classification system, Urgency Disposition
Groups, and Urgency Related Group (URG), was origin-
ally developed in Western Australia [49] to group patient
presentations into categories. The IHPA implemented this
system nationally in 2012, and it has since undergone sev-
eral revisions commissioned by the IHPA [50]. Each ED
presentation was coded to a URG using the triage cat-
egory, discharge destination and the primary reason for at-
tending the ED (ICD-10-AM). The cost attributed to each
URG for each ED presentations was assigned using the
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average cost per presentation as reported by the NHCDC
Report (available online) [38–41] for the relevant year.
MBS and PBS costs
Briefly, Australia’s universal healthcare system (Medicare),
provides free and subsidized medical services under MBS
and PBS. For services covered by MBS, if there is a gap be-
tween the rebate paid by Medicare and the amount
charged by the service provider, the individual will incur
an out-of-pocket co-payment. In some cases, the service
provider may ‘bulk-bill’ a patient, or charge the amount
equal to the Medicare rebate, resulting in no individual
co-payment. For prescription pharmaceuticals, the indi-
vidual will be charged up to the set patient co-payment
for concession (low income card holders) and general pa-
tients. Australia has several safety net arrangements for in-
dividuals and family groups with high OOPE (two
Medicare Safety Nets, and one PBS Safety Net). Once an
individual or family group reaches a given amount on
co-payments for a calendar year, they will receive a higher
government subsidy, resulting in reduced patient co-pay-
ments [51]. Furthermore, Indigenous Australians living
with, or at risk of chronic disease may also be eligible to
receive prescription pharmaceuticals at reduced cost
through the Closing the Gap (CTG) PBS Co-payment
Programme [52]. However, hospital prescriptions are ex-
cluded from this programme [52].
The MBS and PBS data includes date of service/dis-
pensing, MBS/PBS item number, patient postcode,
provider/pharmacy postcode, and total fee charged,
rebate paid, and patient co-payment.
Statistical analysis
Initially, descriptive analysis was undertaken to describe
the social and demographic characteristics of the sample,
and weighted sample. Then the total cost for the first
12-months post-diagnosis for the five types of healthcare
expenditure: hospital episodes, ED presentations, MBS
items, PBS items, and patient co-payments are presented
for the broad type of cancer, and the population groups of
interest. We also present the average total healthcare cost
per person (to the Australian healthcare system), and the
average patient co-payment per person during the first
12-months following a diagnosis. We chose to include the
standard deviation, as in many cases, the standard devi-
ation was greater than the mean, indicating a wide disper-
sion of the costs.
Finally, the total cost of cancer for the first 12-months
following diagnosis for each of the five types of healthcare
were modelled with a generalized linear model using a
gamma distribution, with a log link function. This in-
cluded the number of months the patient survived as an
offset to the model. The analysis was limited to include
adults (≥ 18 years at diagnosis), and only to those who had
costs for the healthcare type used in the model. Independ-
ent variables included in the analysis were sex, age at
diagnosis, Indigenous status (reference group = non-Indi-
genous Australians), rurality (three categories; reference
group =metropolitan), IRSD quintiles (reference group =
Q1 (most disadvantaged)) and broad cancer type (18 cat-
egories; reference group = tracheal, bronchus and lung
cancer).
All analyses were undertaken using SAS V9.4 (SAS
Institute Inc., Cary, NC, USA). Weighted estimates are
presented, unless otherwise stated.
Human Research Ethics approval was obtained from the
Townsville Health and Hospital Service Human Research
Ethics Committee (HREC) (HREC/16/QTHS/11), AIHW
(EO2017/1/343) and James Cook University HREC
(H6678). Permission to waive consent was approved from
Queensland Health under the Public Health Act 2005. No
identifiable information was provided to the authors.
Results
CancerCostMod cancer incidence
In total, 25,553 individuals were diagnosed with a new can-
cer in Queensland between July 2011 and June 2012. Once
weighted, this represents 123,900 Australians. Table 1 re-
ports the demographic characteristics of our model for all
cancers, and for the five most commonly diagnosed can-
cers in Australia. Our original QCR dataset had complete
Indigenous status for 87% of our records, which matches
an audit of Queensland Health hospital admission records
in 2011–12 [27]. After imputation, we estimated that 2129
of our model were Indigenous Australians.
Table 2 reports the age-standardised incidence rates for
our weighted model, compared to the national age-stan-
dardised incidence rates for new cases diagnosed in 2012.
The CancerCostMod age-standardised incidence rate for
the five most commonly diagnosed cancers in Australia
are similar to the national age-standardised incidence rate
for new cases in 2012.
Cost of cancer during the first 12-months post-diagnosis
by broad cancer type
The total initial cost associated with newly diagnosed
cancer for the healthcare system was $4.3 billion, and
total patient co-payment was $127.7 million. Hospital
episodes accounted for 77% of the healthcare expend-
iture, followed by PBS (14%) and MBS 6%. Table 3
shows the total cost of cancer for the first 12-months
following diagnosis for all cancers combined, and for
each broad cancer type (excluding ‘bone’ and ‘other
thoracic and respiratory organs’ cancers due to sample
size). The most expensive cancers to the healthcare
system were cancers of the blood and lymphatic
Bates et al. Health Economics Review            (2018) 8:28 Page 5 of 12
system, followed by colorectal cancer and breast can-
cer. Colorectal cancer was the most expensive cancer
in regards to hospital episodes, and cancers of the
blood and lymphatic system had the highest MBS and
PBS rebate costs. During the first 12-months, cancers
of the eye, brain and other parts of the central ner-
vous system (CNS) accounted for the highest average
cost per person to the Australian healthcare system,
followed by cancers of the blood and lymphatic sys-
tem. The most expensive cancers in regards to patient
co-payments were cancers of the blood and lymphatic
system, followed by breast cancer and colorectal can-
cer. The average patient co-payment costs per person
were highest for cancers of the blood and lymphatic
system, followed by cancers of the eye, brain and
other parts of the central nervous system (CNS).
Table 1 Demographic characteristics of CancerCostMod for all cancers combined, and most commonly diagnosed cancersa
All cancers Breast cancer Prostate cancer Colorectal cancer Tracheal, bronchus
and lung cancer
Melanoma of
the skin
Actual n 25,600 3100 4200 2900 2100 3300
Weighted N (%) 123,900 15,400 (12.5) 20,700 (16.7) 14,800 (11.9) 11,100 (9.0) 12,300 (9.9)
Died within 12-months post-diagnosis (%) 25,100 (20.2) 700 (4.2) 1000 (4.6) 2400 (16.3) 6400 (57.7) 400 (3.1)
Age group
≤ 17 (%) 1000 (0.8) – – – – –
18 to 44 (%) 9300 (7.5) 1800 (12.0) 100 (0.6) 700 (4.7) 200 (1.6) 1800 (14.6)
45 to 64 (%) 42,700 (34.5) 7600 (49.1) 7800 (37.7) 4100 (27.7) 2900 (26.3) 4500 (36.4)
≥ 65 (%) 70,900 (57.2) 6000 (38.9) 12,800 (61.8) 10,000 (27.6) 8000 (72.1) 6000 (48.7)
Sex
Male (%) 69,300 (55.9) 100 (0.7) 20,700 (100) 8100 (54.9) 6500 (58.4) 7200 (58.4)
Female (%) 54,600 (44.1) 15,300 (99.3) n/a 6700 (45.1) 4600 (41.6) 5100 (41.6)
Indigenous status
Non-Indigenous Australian (%) 121,800 (98.3) 15,200 (98.4) 20,500 (99.0) 14,600 (99.1) 10,800 (97.3) 12,100 (98.8)
Indigenous Australian (%) 2100 (1.7) 300 (1.6) 200 (1.0) 100 (0.9) 300 (2.7) 100 (1.2)
Ruralityb
Metropolitan (%) 58,500 (47.5) 7800 (50.5) 9100 (44.1) 6700 (45.9) 5000 (45.2) 6100 (49.7)
Regional (%) 54,500 (44.2) 6400 (41.7) 9600 (46.5) 6600 (45.1) 5100 (45.8) 5300 (43.7)
Remote (%) 10,200 (8.3) 1200 (7.8) 1900 (9.4) 1300 (9.1) 1000 (9.0) 800 (6.7)
IRSDc Quintilesb
Q1 (Most disadvantaged) (%) 11,300 (9.2) 1100 (7.2) 2100 (10.2) 1400 (9.8) 1300 (11.6) 1000 (8.2)
Q2 (%) 5700 (4.7) 800 (5.0) 900 (4.3) 700 (4.6) 600 (5.3) 500 (4.3)
Q3 (%) 19,900 (16.2) 2500 (16.3) 3400 (16.5) 2500 (16.7) 1900 (17.5) 1800 (14.7)
Q4 (%) 56,000 (45.5) 6700 (43.7) 9300 (45.2) 6700 (45.7) 4900 (44.5) 5900 (47.9)
Q5 (Least disadvantaged) (%) 30,200 (24.5) 4300 (27.8) 4900 (23.8) 3400 (23.1) 2300 (21.1) 3000 (24.9)
a Weighted results reported (except in the first row), and rounded to the nearest 100. Weighted values less than 100 are not reported
b Excluding individuals with missing postcodes
c Index of Relative Socio-Economic Disadvantage
Table 2 Australian and CancerCostMod Cancer Incidence
Broad cancer group National new
cases, 2012
National incidence
rate (a)
CancerCostMod cases CancerCostMod
incidence rate (a)
All cancers 121,693 482.85 123,915 492.75
Breast cancer (female only) 15,337 120.42 15,335 120.56
Prostate cancer (male only) 20,687 168.25 20,687 168.37
Colorectal cancer 14,793 58.46 14,774 58.54
Tracheal, bronchus and lung cancer 11,114 43.78 11,104 43.52
Melanoma of the skin 12,250 49.51 12,250 49.42
(a) Incidence rates are standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population
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Cost of cancer during the first 12-months post-diagnosis
by population group
We then aimed to describe the cost of cancer for the
first 12-months post-diagnosis by Indigenous status,
rurality, and socioeconomic disadvantage, as shown in
Table 4. The average total healthcare cost per person
was greater for Indigenous people diagnosed with
cancer in the first 12-months, compared to non-Indi-
genous people diagnosed with cancer. However, the
average patient co-payment was greater for
non-Indigenous people diagnosed with cancer, com-
pared to Indigenous people diagnosed with cancer.
Table 4 also shows that the average total healthcare
cost per person was greater for people from the most
disadvantaged quintile (Q1), and the lowest for people
in the least disadvantaged quintile (Q5). Conversely,
the average patient co-payment was greatest for people in
the least disadvantaged quintile (Q5), and lowest for
people in the most disadvantaged quintile (Q1).
Finally, we conducted five generalized linear models
to predict costs, limiting our analyses to adults only
(≥ 18 years), adjusting for sex, Indigenous status, rur-
ality, IRSD quintile, age at diagnosis, and broad can-
cer type (co-efficients not shown). Table 5 shows the
abbreviated output for the five types of cost: hospital
episodes, ED presentations, MBS rebates (excluding
hospital items), PBS rebates, and patient co-payments.
Indigenous Australians had significantly higher costs
for hospital episodes (22% higher) and ED presenta-
tions (23% higher), but significantly lower costs for
MBS rebates (8% lower), PBS rebates (18% lower), and
patient co-payments (61% lower) compared to
Table 3 Total cost of cancer during the first 12-months post-diagnosis by cancer typea
Cost To The Australian Healthcare System (AUD) Patient co-paymente
(AUD)
Nb Hospital
episodesc
ED
presentations
MBS
rebated
PBS rebate Total cost to
the healthcare
system
Average
healthcare cost
per person (SD)
Total Average per
person (SD)
All cancers combined 123,900 3,302,933,000 88,103,100 263,243,600 631,804,300 4,286,083,900 34,600 (41300) 127,673,700 1000 (2000)
Prostate cancer 20,700 279,788,000 6,416,200 36,828, 600 38,650,600 361,683,300 17,500 (17,300) 16,324,000 800 (1200)
Breast cancer 15,400 266,860,700 6,744,700 36,690, 600 170,956,200 481,252,200 31,200 (29,700) 21,040, 900 1400 (1500)
Colorectal cancer 14,800 581,675,500 11,849,400 30,563,000 71,878,900 695,966,800 47,100 (38,200) 16,979,500 1100 (1800)
Blood and lymphatic
system
13,300 564,265,300 13,286,600 40,503,100 176,947,100 795,002000 59,800 (70,800) 24,655,400 1900 (4100)
Melanoma of the
skin
12,300 53,047,300 1,575,700 23,174,800 12,506,700 90,304,500 7400 (12600) 4,945,100 400 (500)
Tracheal, bronchus
and lung cancer
11,100 396,063,600 15,618,400 24,164,600 45,331,000 481,177,600 43,300 (34,700) 10,168,700 900 (1700)
Digestive organs 10,100 394,784,900 12,668,100 20,303,100 31,119,600 458,875,800 45,500 (36,800) 11,273,000 1100 (2000)
Cancers of the
urinary tract
6200 181,697,200 5,022300 10,703,000 17,623,000 215,045,500 34,700 (31800) 4,816,000 800 (1100)
Gynaecological
cancers
5200 138,156,900 3,121,600 10,475,000 16,774,700 168,528,200 32,300 (31500) 5,171,800 1000 (1600)
Head and neck 4000 118,588,400 2,478,200 10,264,700 9,019,700 140,351,100 34,900 (45,500) 2,374,400 600 (1200)
Other or ill-defined
cancers
2700 67,701,500 2,316,900 4,295,300 6,051400 80,365,200 29,600 (29,700) 2,239,700 800 (1700)
Thyroid and other
endocrine glands
2600 48,531,700 799,400 4,195,500 3,631,300 57,157,900 22,000 (34,400) 1,180,600 500 (600)
Eye, brain and CNS 1900 101,300,100 3,113,900 3,324,700 17,342,800 125,081500 64,700 (70,400) 2,830,000 1500 (2300)
Mesothelioma, Kaposi
Sarcoma, and
soft tissue
1600 62,604,600 1,882,200 3,245,200 9,187,200 76,919,200 47,100 (46100) 2,080,100 1300 (2200)
Male genital organs,
exc prostate
900 17,921,400 678,900 2,190,200 2,267,400 23,057, 900 25,000 (30,400) 643,200 700 (1200)
Other skin cancer 800 11,920,400 283,300 1,749,400 1,456,800 15,409,900 18,600 (28100) 541,900 700 (1100)
a Weighted results reported, and rounded to the nearest 100
b Excluding broad cancer types with less than 500 individuals (‘bone’, and ‘other thoracic and respiratory organs’)
c Admitted and non-admitted hospital episodes
d MBS rebate, excluding items included as non-admitted hospital episodes
e MBS and PBS patient co-payment
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non-Indigenous Australians. The costs for hospital
episodes had significantly higher costs in the first
12-months post-diagnosis with increasing remoteness,
6% for people living in inner and outer regional areas,
and 15% higher for people living in remote and very
remote areas compared to those living in metropol-
itan areas. People living in remote and very remote
areas had 10% lower costs for MBS rebates and 10%
higher PBS rebate costs. Compared to those living in
the most disadvantaged areas (IRSD Q1), those in
quintiles 3–4 had decreasing costs associated with
hospital episodes. There were no differences in the
costs of ED presentations for IRSD quintiles. The
costs incurred for MBS and PBS rebates and also pa-
tient co-payments increased as the IRSD quintile in-
creased (moved towards the least disadvantaged).
Discussion
The use of administrative health data is growing in
Australia and is supported by a number of Australian
Government agencies [53]. There are many advantages
of using administrative data for research, including being
non-intrusive to the target population, no (or low) cost
for data collection (but there may be a cost-recovery
charge), and the ability to capture a large population.
Administrative data has advantages over sample data,
which relies on self-reported information from patients,
and also excludes patients who have passed away. There
are a growing number of international studies which
have used linked administrative data to describe the
patterns and cost of cancer. For example, recent
international studies have used administrative data to
describe the excess cost of cancer in New Zealand
[54], Canada [55], and England [56]. Our model, Can-
cerCostMod does not seek to describe the excess cost
of cancer compared to the general population, but ra-
ther, describe the distribution of costs for population
groups experiencing poorer health outcomes. This
paper aimed to 1) describe the development of our
model, CancerCostMod; 2) to describe the total costs
of cancer in Australia during the first 12-months
post-diagnosis; and 3) to describe the distribution of
the cost of cancer in Australia during the first
12-months post-diagnosis by population group.
We estimated that the total cost to the Australian
healthcare system was $4.3 billion. Hospital episodes
accounted the majority (77%) of the costs to the health-
care system. This is similar to the AIHW national
Table 4 Total cost of cancer for the first 12-months post-diagnosis, by population groups1
Cost To The Australian Healthcare System (AUD) Patient co-payment4
(AUD)
n Hospital
episodes2
ED
presentations
MBS
rebate3
PBS rebate Total cost to
the healthcare
system
Average healthcare
cost per person
(SD)
Total Average per
person (SD)
Weighted total 123,900 3,302,933,000 88,103,100 263,243,600 631,804,300 4,286,083,900 34,600 (41300) 127,673,700 1000 (2000)
Indigenous status
Non-Indigenous
Australian
121,800 3,233,868,900 85,643,100 259,009,200 623,618,600 4,202,139,700 34,500 (41100) 126,913,100 1000 (2000)
Indigenous
Australian
2100 69,064100 2,459,900 4,234,500 8,185,700 83,944,200 40,100 (48100) 760,600 400 (800)
Rurality5
Metropolitan 58,500 1,485,140,700 38,505,200 125,884,200 306,909,000 1,956,439,200 33,500 (38,200) 65,570,600 1100 (1900)
Regional 54,500 1,495,270,400 42,165,900 116,837,100 270,755,900 1,925,029300 35,300 (42300) 52,061400 1000 (1900)
Remote 10,200 311,295,100 6,805,500 19,718,200 52,844,900 390,663,700 38,200 (51900) 9,831,600 1000 (2500)
IRSD6 Quintiles5
Q1 (Most
disadvantaged)
11,300 349,061100 11,248,900 21,232,900 47,295,500 428,838,500 38,000 (43000) 9,226,300 800 (1900)
Q2 5700 160,726,000 3,180,500 11,653,000 28,801,500 204,361,000 35,700 (42300) 4900,200 900 (1800)
Q3 19,900 554,607,600 14,727,500 41,726,900 102,484,100 713,546,100 35,900 (46,800) 17,757,000 1100 (1800)
Q4 56,000 1,469,376,800 42,010,300 128,352,200 288,661,500 1,928,400,700 34,400 (40,400) 59,401,200 1100 (1800)
Q5 (Least
disadvantaged)
30,200 757,934,600 16,309,300 59,474,600 163,267,300 996,985,900 33,000 (38,300) 36,179,100 1200 (2000)
1 Weighted results reported, and rounded to the nearest 100
2 Admitted and non-admitted hospital episodes
3 MBS rebate, excluding items included as non-admitted hospital episodes
4 MBS and PBS patient co-payment
5 Excluding individuals with missing postcodes
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report, which estimated that hospital admitted patient
services accounted for 79% of the national healthcare
system expenditure in 2008–09 [18]. Likewise, in other
countries, admitted hospital services have been re-
ported as contributing to the greatest proportion of
cancer-related costs [55, 57, 58]. Initially, we described
the total costs to the healthcare system, and the average
costs per person to the healthcare system by cancer
type, and population group. This initial analysis showed
the average costs per person to the healthcare system
were higher for each of our population groups of inter-
est, compared to their reference group – Indigenous
Australians, people living in remote areas, and people
from the most disadvantaged quintile. We found that
the total cost of cancer during the first 12-months
post-diagnosis was significantly different for Indigenous
Australians, people living in remote and very remote
areas, and people living in areas of greater disadvan-
tage. These differences in costs could be due to differ-
ences in health system use, which we will examine in
future studies.
We estimated that the individual patient co-payment
costs were $127 million in the first 12-months follow-
ing diagnosis. The initial analysis found that the aver-
age co-payment costs were lower for Indigenous
Australians, and people from the most disadvantaged
quintile. After adjusting for age, sex, Indigenous
status, rurality, IRSD quintiles, and broad cancer type,
we found that the patient co-payment costs were
lower for Indigenous Australians compared to non-In-
digenous Australians, for people in inner and outer re-
gional areas compared to metropolitan, and patient
co-payment costs were greater for people from IRSD
quintiles 4 and 5. These findings may be due to Aus-
tralia’s universal healthcare system, and policies in
place, such as the Medicare Safety Nets, the PBS
Safety Net, and the CTG PBS Co-payment Programme
to protect vulnerable population groups and people
with higher healthcare co-payments. We will examine
the differences in patient co-payments in more detail
in future studies.
To our knowledge, this is the first study in Australia to
use individual-level data to estimate the cost of cancer for
Indigenous Australians. A previous report by AIHW and
Cancer Australia reported that the average per person
hospital expenditure for Indigenous Australians was half
of that for non-Indigenous Australians [19]. However, this
report used population-level data and only included hospi-
talizations for which cancer was the primary cause [19].
The advantage of using individual-level data allows us to
Table 5 Five generalized linear models of the cost of cancer for the first 12-months1
Hospital episodes2 ED presentations MBS rebate3 PBS rebates Patient co-payment4
Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE)
Intercept – 8.4819
(0.0526) ***
– 5.4363
(0.0728) ***
– 5.7499
(0.0382) ***
– 6.8536
(0.0721) ***
– 4.7398
(0.0593) ***
Age 1.01 0.0073
(0.0005) ***
1.01 0.0103
(0.0008) ***
1.00 −0.0021
(0.0004) ***
0.99 −0.0109
(0.0008) ***
1.00 0.0033
(0.0006) ***
Female 0.89 −0.1177
(0.0186) ***
0.95 −0.0537
(0.0262) *
0.95 −0.0551
(0.0129) ***
0.85 −0.1597
(0.0234) ***
0.98 −0.0214
(0.0192)
Indigenous Australians 1.22 0.1978
(0.0605) **
1.23 0.2095
(0.0752) **
0.92 −0.0888
(0.0402) *
0.82 −0.1928
(0.0735) **
0.39 −0.9315
(0.0619) ***
Inner and outer
regional area
1.06 0.0557
(0.0182) **
1.02 0.0196
(0.0275)
0.99 −0.0138
(0.0126)
1.04 0.0366
(0.0231)
0.94 −0.0571
(0.0189) **
Remote and very
remote area
1.15 0.1401
(0.0296) ***
1.03 0.0322
(0.0454)
0.90 −0.1092
(0.0207) ***
1.10 0.0912
(0.0381) *
0.98 −0.0219
(0.0311)
IRSD5 Q2 1.01 0.0091
(0.0415)
1.00 0.0004
(0.0626)
1.07 0.0675
(0.0289) *
1.05 0.0474
(0.0519)
1.00 −0.0026
(0.0432)
IRSD5 Q3 0.94 −0.0619
(0.0309) *
1.01 0.0097
(0.0420)
1.08 0.0805
(0.0216) ***
1.11 0.1053
(0.0389) **
1.00 −0.0020
(0.0324)
IRSD5 Q4 0.90 −0.1042
(0.0275) ***
0.98 −0.0215
(0.0368)
1.18 0.1642
(0.0193) ***
1.17 0.1582
(0.0348) ***
1.23 0.2033
(0.0289) ***
IRSD5 Q5 (least disadvantaged) 0.88 −0.1297
(0.0323) ***
0.94 −0.0603
(0.0467)
1.00 0.0016
(0.0226)
1.19 0.1703
(0.0411) ***
1.32 0.2746
(0.0338) ***
* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
1 Adjusted for age at diagnosis, sex, Indigenous status, rurality, IRSD quintiles, and broad cancer type
2 Admitted and non-admitted hospital episodes
3 MBS rebate, excluding items included as non-admitted hospital episodes
4 MBS and PBS co-payment is the cost to the patient
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determine if there are differences in health system use,
and cost between Indigenous and non-Indigenous people.
Further studies using CancerCostMod will examine these
differences in more detail.
This is the first model in Australia, which aims to
describe the healthcare system costs and patient
co-payment costs for these population groups experien-
cing inequalities. Previous Australian studies have re-
ported higher OOPE for rural patients with cancer [15,
16]. Recently, Newton et al. (2018) reported that the
highest OOPE was due to surgery (23%), tests (20%),
and accommodation (12%) [16]. Whereas, Gordon et al.
(2009) reported travel costs accounting for the greatest
proportion of patient OOPE (71%), followed by medical
appointments (10%), and PBS co-payments (9%) [15].
Although CancerCostMod only estimates the patient
co-payments for primary health care and prescription
pharmaceuticals, it has the advantage of using adminis-
trative data, and thus is not subject to selection bias
(recruitment and loss-to follow-up), or recall bias in
recalling healthcare expenditure.
A strength of this study is that the base population
includes everyone diagnosed with cancer in Queens-
land, and 3 years of follow-up data were obtained
using linked administrative data. Our data have then
been weighted to the Australian population to allow
us to estimate the healthcare expenditure of cancer to
the Australian healthcare system, and the patient
co-payments for Australians diagnosed with cancer.
A common limitation of Australian health studies, is
the completeness of Indigenous status on health re-
cords. We used multiple imputation to assign Indigen-
ous status to missing records in our original QCR
cohort. As reported, once weighted, our model included
2129 Indigenous Australians. There are currently no re-
liable data on the number of new cancer cases for Indi-
genous Australians for each jurisdiction in Australia.
The most recent national AIHW data reports that in
2012, approximately 1343 new cancer cases were diag-
nosed in Indigenous Australians [59]. However, this es-
timate is based on five (of eight) jurisdictions only, in
which the majority (90%) of Indigenous Australians live
[59]. There is also varying levels of completeness of In-
digenous status for each jurisdiction (from 2% un-
known, to 18% unknown) [59]. Therefore, this national
estimate may be underestimating the true incidence of
cancer in Indigenous Australians [59]. One of the 2015
National Aboriginal and Torres Strait Islander Cancer
Framework priorities is to “strengthen the capacity of
cancer related services and systems to deliver good
quality, integrates services that meet the needs of Abo-
riginal and Torres Strait Islander people” [60], and calls
for improved recording of Indigenous status, and rec-
ommends the use of linked administrative data to look
at patterns of care for Indigenous Australians in order
to meet one of their priorities [60]. CancerCostMod
uses individual-level data, which allows us to evaluate
the service use and to quantify the cost of care for Indi-
genous Australians.
Administrative data have inherent weaknesses, pri-
marily that the data are not collected for the purpose of
research. For example, we were unable to estimate the
cost of cancer by clinical staging, as this is not routinely
collected by the QCR. The QCR does not collect indi-
vidual or household financial information, therefore, we
used aggregated area-level data to classify an individ-
ual’s level of socioeconomic disadvantage. We were also
unable to analyze individual physiological, biological or
clinical factors, which are considered by the treating
specialist and may alter the suitability of different treat-
ment options. The patient co-payment costs will be
limited to costs incurred for MBS and PBS items, which
excludes patient co-payment costs for private or non-
prescription pharmaceuticals, private health insurance
premiums, or hospital excess, or travel/accommodation
costs. Finally, we sought to describe the cost of ED pre-
sentations for people with cancer. The IHPA first used
the ED Classification System in the National Efficient
Price Determination in 2012–13 [45]. The IHPA
NHCDC annual reports include the average cost of
each ED presentation from 2011, however, there have
been several changes to the ED URG classification sys-
tem and we have included the estimation of the costs
of ED presentations separately to the hospital episodes.
Conclusions
These findings are of interest to policy makers and health-
care providers, as they provide an evaluation of the total
cost of cancer. To ensure an equitable healthcare system, it
is first important to determine if there are any inequalities
in relation to healthcare service use and expenditure
amongst population groups whom experience poorer
health outcomes. This paper describes the development of
CancerCostMod, Australia’s first model of health service
use, healthcare expenditure, and patient co-payment ex-
penditure for people with cancer. CancerCostMod can be
used to fill the gap by quantifying the current health system
use, healthcare expenditure and patient co-payment costs
for population groups experiencing poorer health outcomes
- Indigenous people, people living in rural and remote
areas, and socioeconomically disadvantaged persons. We
found significant differences in healthcare expenditure and
patient co-payments for the first 12-months following a
cancer diagnosis for each of these population groups. Can-
cerCostMod can be used to look at the cost from different
perspectives for the first 3 years, with the potential to in-
crease the cohort enrolment period and study period.
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